In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

Targets Key Regulator Of Neurotransmitters

 
• By Sushmita Panda
  
Neurocrine Biosciences
Neurocrine Biosciences reports further details of Phase II findings for its novel schizophrenia candidate. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas